证券代码：002332 证券简称：仙琚制药 公告编号：2025-029 浙江仙琚制药股份有限公司 关于噻托溴铵吸入喷雾剂药品注册申请获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局下发的噻托溴铵吸入喷雾剂境内生产药品注册受理通知书，现将相关情况 公告如下： 品注册工作进入了审评阶段，公司将积极推进后续相关工作，如顺利通过审批将 丰富公司的产品线，有利于提升公司的市场竞争力。药品注册审批工作流程有一 定时间周期，存在不确定性因素，敬请广大投资者审慎决策，注意投资风险。 二、噻托溴铵吸入喷雾剂的相关情况 噻托溴铵吸入喷雾剂，规格为每瓶 60 喷，每喷递送剂量为噻托溴铵 2.5μg （按 C₁₉H₂₂NO₄S₂计），药液浓度含噻托溴铵 0.2262mg/ml（按 C₁₉H₂₂NO₄S₂计）， 参比制剂为原研药噻托溴铵吸入喷雾剂，持证商是 Boehringer Ingelheim International GmbH，商品名为 Spiriva® Respimat®。适应症为用于慢 ...

仙琚制药(002332.SZ)公告称，公司于近日收到国家药品监督管理局下发的噻托溴铵吸入喷雾剂境内生 产药品注册受理通知书。噻托溴铵吸入喷雾剂规格为每瓶60喷，每喷递送剂量为噻托溴铵2.5μg，药液 浓度含噻托溴铵0.2262mg/ml。该品种境内生产药品注册工作进入了审评阶段，如顺利通过审批将丰富 公司的产品线，有利于提升公司的市场竞争力。但药品注册审批工作流程有一定时间周期，存在不确定 性因素，敬请广大投资者审慎决策，注意投资风险。 ...

一、增资概述 浙江萃泽医药科技有限公司（以下简称"萃泽医药"）系浙江仙琚制药股份 有限公司（以下简称"公司"）的参股公司，公司持有其 37.3879%的股权。近 日，公司收到萃泽医药拟增加注册资本的通知，考虑到经营需求，萃泽医药注册 资本拟由 1529.0243 万元增资到 1618.0152 万元，拟增加注册资本 88.9909 万元， 增资价格为 37.0825 元/股。公司结合实际经营情况，拟放弃本次股权增资的优 先认缴出资权。 本次增资拟由以下 5 家投资方参与：仙居县海纳包装有限公司出资 1200 万 元人民币，王焕勇出资 900 万元人民币，王宝军出资 600 万元人民币，郑旭芬出 资 300 万元人民币，楼晓炯出资 300 万元人民币。拟参与增资的 5 家认购方以现 金出资合计 3300 万元人民币,认购萃泽医药的新增注册资本 88.9909 万元。本次 增资完成后，公司持有萃泽医药的股权比例由原来的 37.3879%降至 35.3316%。 本次放弃萃泽医药增资优先认购权事项已经公司第八届董事会第十四次会 议审议通过，根据《公司章程》、公司《投资管理制度》规定，本次放弃萃泽医 药增资优先认购权 ...

浙江仙琚制药股份有限公司（以下简称"公司"）第八届董事会第十四次会 议通知已于 2025 年 6 月 19 日以电子邮件方式向公司全体董事发出，会议于 2025 年 6 月 25 日以通讯方式召开。本次会议应参加董事 9 名，实际参加董事 9 名， 会议由公司董事长张宇松先生召集并主持。本次会议的召集、召开符合《中华人 民共和国公司法》和《公司章程》的有关规定。全体与会董事以记名投票方式通 过以下决议： 证券代码：002332 证券简称：仙琚制药 公告编号：2025-027 浙江仙琚制药股份有限公司 第八届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 董事会 2025 年 6 月 26 日 会议以 9 票同意，0 票弃权，0 票反对，审议通过了《关于放弃参股公司增 资扩股优先认缴出资权的议案》。 《关于放弃参股公司增资扩股优先认缴出资权的公告》详见 2025 年 6 月 26 日的《证券时报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资讯网 （www.cninfo.com.cn）。 特此公告。 浙江仙琚制药股份有限公司 ...

Core Viewpoint - The recent penalty imposed by the State Administration for Market Regulation has exposed a hidden monopoly network in the pharmaceutical industry, with significant financial repercussions for the involved parties [1]. Group 1: Monopoly Scheme - A gathering organized by an individual named Guo in November 2021 led to a verbal agreement among four pharmaceutical companies to stop price competition and collectively raise prices [2]. - To evade regulatory scrutiny, the companies coordinated price hikes through Guo, using communication methods such as WeChat and phone calls [2]. Group 2: Price Surge - Following the agreement, the four companies collectively halted supply in January 2022, causing a severe market supply shortage [3]. - The price of the raw material dexamethasone skyrocketed from 8,000 yuan per kilogram to 13,800 yuan, marking a 72% increase [3]. - The price of dexamethasone injection surged from 0.35 yuan per unit to nearly 100 yuan, with some hospitals in Guangxi purchasing it at 60 yuan per unit, reflecting an alarming increase [3]. Group 3: Penalties and Legal Framework - The leniency policy in antitrust cases played a crucial role, with Tianyao Pharmaceutical receiving an 80% reduction in fines after self-reporting and providing key evidence, resulting in a total penalty of 69.19 million yuan [4]. - In contrast, Xianju Pharmaceutical faced a maximum fine of nearly 195 million yuan due to its failure to apply for leniency [4]. - All responsible individuals from the four companies were fined 600,000 yuan each [4]. Group 4: Regulatory Environment - The case is part of a broader trend, with multiple antitrust cases in the pharmaceutical sector being investigated in recent years, including those involving acetic acid and other raw materials [5]. - The regulatory framework has been strengthened with the introduction of the "Raw Material Drug Antitrust Guidelines" in 2021 and the "Drug Sector Antitrust Guidelines" set for 2025, establishing a comprehensive regulatory system [5]. - Antitrust enforcement is increasingly focused on essential sectors like pharmaceuticals, with new major cases leading to price reductions of up to 62% for involved drugs [5].

Core Viewpoint - Four pharmaceutical companies, including Tianjin Pharmaceutical Co., Ltd. (Tianjin Pharma), Zhejiang Xianju Pharmaceutical Co., Ltd. (Xianju Pharma), Jiangsu Lianhuan Pharmaceutical Co., Ltd. (Lianhuan Pharma), and Xi'an Guokang Ruijin Pharmaceutical Co., Ltd., were fined a total of 362 million yuan for price-fixing of dexamethasone raw materials, with Tianjin Pharma being penalized for the fourth time for similar monopolistic behavior [1][2][4]. Group 1: Companies Involved - Tianjin Pharma, Xianju Pharma, Lianhuan Pharma, and Xi'an Guokang Ruijin Pharma were involved in a price-fixing scheme for dexamethasone, leading to a significant increase in prices from 8,000 yuan/kg to 13,000 yuan/kg between February 2022 and March 2024 [2][4]. - Tianjin Pharma has a history of monopolistic practices, having been penalized multiple times since 2021 for various violations of antitrust laws [4][5]. - Lianhuan Pharma's fine represents 72.53% of its net profit, significantly impacting its financial performance [6][8]. Group 2: Regulatory Actions - The Tianjin Municipal Market Supervision Administration imposed fines based on the companies' previous year's sales, totaling 355 million yuan, along with confiscation of illegal gains [2][7]. - The regulatory body emphasized the importance of maintaining fair competition in the pharmaceutical sector and indicated a commitment to stricter enforcement of antitrust laws [2][4]. - Lianhuan Pharma has submitted a hearing request to reduce its penalties, but the regulatory authority rejected its arguments, affirming the validity of the evidence against the company [7]. Group 3: Financial Impact - Lianhuan Pharma reported revenues of 2.174 billion yuan and 2.160 billion yuan for 2023 and 2024, respectively, with net profits declining by 4.5% and 37.66% [6][8]. - The fine imposed on Lianhuan Pharma will reduce its net profit for 2025 by approximately 61.04 million yuan [8]. - Tianjin Pharma's market influence is significant, with a strong presence in the domestic market for steroid hormone raw materials [5].

Core Viewpoint - The article discusses the significant administrative penalties imposed on Xianju Pharmaceutical for participating in a price-fixing agreement regarding the raw material Dexamethasone Sodium Phosphate, highlighting the implications for corporate governance and compliance standards in the pharmaceutical industry [2][3][4]. Group 1: Penalty Details - The State Administration for Market Regulation imposed a total fine of 362 million yuan on four companies involved in the price-fixing agreement, with Xianju Pharmaceutical facing the highest penalty of 195 million yuan, which includes the confiscation of illegal gains and an 8% fine based on 2023 sales [2][3]. - The price of Dexamethasone Sodium Phosphate increased from 8,000 yuan per kilogram to 13,800 yuan per kilogram, marking a 62.5% rise due to the collusion among the companies [3]. Group 2: Corporate Governance and Compliance - The price-fixing behavior reflects a significant gap in Xianju Pharmaceutical's internal governance and compliance measures, contradicting their stated commitment to fair competition and ethical business practices [4][8]. - The company’s ESG report emphasizes integrity and compliance, yet the actions taken during the price-fixing period indicate a failure to uphold these standards, raising concerns about the effectiveness of their ethical framework [4][8]. Group 3: Information Disclosure Issues - Xianju Pharmaceutical faced criticism for the delayed disclosure of the penalty information, which was only briefly mentioned in the annual report, leading to investor concerns about transparency and the potential impact on investment decisions [9][10]. - The company disclosed the penalty details on page 182 of the annual report, making it difficult for investors to locate this critical information, which raises questions about the company's commitment to transparent communication [10][12]. Group 4: Investor Reactions - During an earnings call, investors raised numerous questions regarding the penalty and the company's disclosure practices, indicating significant concern over the implications for profitability and stock performance [15]. - The company's responses to investor inquiries about the penalty's impact were deemed insufficient, failing to address concerns about profit, stock price decline, and potential insider information leaks [15].

Core Viewpoint - The National Market Supervision Administration has imposed a total fine of 355 million yuan on four pharmaceutical companies for colluding to raise the price of dexamethasone phosphate raw materials, which saw a price increase of up to 282 times [1] Group 1: Companies Involved - Four companies involved in the price-fixing scheme include Tianjin Pharmaceutical Co., Jiangsu Lianhuan Pharmaceutical Co., Xi'an Guokang Ruijin Pharmaceutical Co., and Zhejiang Xianju Pharmaceutical Co. [1] - The organizer of the collusion, identified as Guo, was fined the maximum amount of 5 million yuan, while four responsible individuals from the companies were fined 600,000 yuan each [1] Group 2: Price Increases - Dexamethasone phosphate raw material prices were raised significantly, with Tianjin Pharmaceutical increasing prices from 9,000 yuan/kg to 13,800 yuan/kg, and Xi'an Guokang Ruijin raising prices from 7,900 yuan/kg to between 10,000 and 38,000 yuan/kg [1] - Zhejiang Xianju Pharmaceutical raised prices from 8,200 yuan/kg to 10,000 yuan/kg, while Jiangsu Lianhuan increased prices from 7,800 yuan/kg to 15,000 yuan/kg [1] Group 3: Market Impact - The collusion led to a severe market supply shortage, with the price of dexamethasone phosphate injection skyrocketing from 0.35 yuan per dose to 98.76 yuan per dose, marking a staggering increase of 282 times [1] - As of March 7, 2024, the monopolistic pricing of dexamethasone phosphate raw materials was still being enforced [1] Group 4: Legal Consequences - The total illegal gains from the price-fixing scheme were calculated as follows: Tianjin Pharmaceutical Co. 42,764,400 yuan, Zhejiang Xianju Pharmaceutical Co. 23,746,680 yuan, Xi'an Guokang Ruijin Pharmaceutical Co. 24,763,156 yuan, and Jiangsu Lianhuan Pharmaceutical Co. 17,899,200 yuan [1] - The fines imposed on the four companies amounted to 355 million yuan, which includes the confiscation of illegal gains and an additional penalty of 8% of the previous year's sales [1]

Group 1 - The State Administration for Market Regulation announced two antitrust enforcement cases in the pharmaceutical sector during a press conference on June 13, 2023 [1] - In the case involving the raw material drug Dexamethasone Sodium Phosphate, four companies collectively raised the price from 8,000 yuan per kilogram to 13,000 yuan, resulting in a total fine of 362 million yuan [1][2] - The companies involved in the price-fixing agreement included Tianjin Jiyuan Pharmaceutical Co., Zhejiang Xianju Pharmaceutical Co., Jiangsu Lianhuan Pharmaceutical Co., and Xi'an Guokang Ruijin Pharmaceutical Co. [1] Group 2 - The Tianjin Market Regulation Commission imposed administrative penalties, including a maximum fine of 5 million yuan on individual Guo, and confiscated illegal gains from the four companies, totaling 354 million yuan [2] - Each of the four companies was fined 8% of their previous year's sales for participating in the price-fixing agreement, and four responsible individuals were fined 600,000 yuan each [2] - In March 2023, authorities also penalized companies involved in a separate case regarding the injection of Neostigmine Methylsulfate, with total fines amounting to 223 million yuan [2]

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. was fined approximately 61.04 million yuan for violating the Anti-Monopoly Law during the sale of the raw material dexamethasone phosphate sodium, marking a significant enforcement action under the revised law [1][2][4][5]. Summary by Relevant Sections Administrative Penalties - The total fines from this series of cases exceed 360 million yuan, with Lianhuan Pharmaceutical's fine being a substantial part of this total [7]. - Lianhuan Pharmaceutical was fined 61.04 million yuan, which includes the confiscation of illegal gains of 17.89 million yuan and a fine of approximately 43.14 million yuan based on 8% of its 2023 sales [4][8]. Case Background - The case involved four pharmaceutical companies colluding to raise prices of dexamethasone phosphate sodium, a critical drug for treating severe COVID-19 cases, leading to increased costs for patients and healthcare systems [8][10]. - The collusion lasted for about two and a half years, starting from November 20, 2021, when the agreement was made during a meeting organized by an individual named Guo [8][21]. Enforcement Trends - The case highlights a trend of stricter enforcement of anti-monopoly laws, particularly in the pharmaceutical sector, where raw material monopolies have become a focus for regulatory bodies [10][11]. - The penalties reflect a dual approach of strict punishment for violations and incentives for compliance, as seen in the differentiated penalties based on cooperation with investigations [13][14]. Implications for the Industry - The case serves as a warning for pharmaceutical companies regarding the risks of horizontal agreements and the need for comprehensive compliance systems to prevent anti-competitive behavior [14]. - Companies are encouraged to establish internal reporting mechanisms and crisis response strategies to mitigate risks associated with anti-monopoly violations [14].